Clinical Research Directory

Inclusion Criteria * Age ≥ 18 years * HIV-1 infected with the potential to have been cured of infection in the course of routine clinical care in the opinion of the treating physician and study team * Have an undetectable plasma HIV-1 RNA and undetectable proviral DNA on suppressive antiretroviral therapy on at least two consecutive measures for at least 6 months * Able and willing to either abstain from sexual activity or use barrier contraceptives during the ATI * Negative serum β-HCG pregnancy test in women with childbearing potential * Have the ability to give appropriate informed consent. Exclusion Criteria * Women who are pregnant or nursing * Women who can become pregnant who are unable or unwilling to use both barrier and pharmacologic contraceptives during the ATI * Previous or current infections that are at high risk of reactivating with immune suppression, in whom there are no effective antimicrobial prophylaxis options * Advanced cardiopulmonary or liver disease * History of untreated solid or hematologic malignancies * Evidence of active viral replication in patients co-infected with Hepatitis B virus (HBV). Treatment should be provided to suppress HBV replication with agents that do not have activity against HIV (ie entecavir) prior to consideration for ATI. * Evidence of viral replication with Hepatitis C virus (HCV), together with evidence of any hepatic fibrosis or inflammation. Such patients should be offered HCV treatment first.